National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting, 49232 [2016-17655]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
49232
Federal Register / Vol. 81, No. 144 / Wednesday, July 27, 2016 / Notices
Name: Advisory Committee on
Heritable Disorders in Newborns and
Children.
Dates and Times: August 25, 2016,
9:00 a.m. to 5:00 p.m. (Meeting time is
tentative.)
August 26, 2016, 9:00 a.m. to 3:00
p.m. (Meeting time is tentative.)
Place: Webcast and In-Person, 5635
Fishers Lane, Rockville, MD 20852.
Status: The meeting will be open to
the public with attendance limited to
space availability. Attendees and
participants also have the option of
viewing the meeting via webcast.
Whether attending in-person or via
webcast, all attendees and participants
must register for the meeting. The
registration link is https://
www.blsmeetings.net/
ACHDNCAugust2016. The registration
deadline is Friday, August 19, 2016,
11:59 p.m. Eastern Time.
Purpose: The Advisory Committee on
Heritable Disorders in Newborns and
Children (Committee), as authorized by
Public Health Service Act, Title XI,
§ 1111, as amended by the Newborn
Screening Saves Lives Reauthorization
Act of 2014 (Pub. L. 113–240) (42 U.S.C.
300b–10), was established to advise the
Secretary of the Department of Health
and Human Services about the
development of newborn screening
activities, technologies, policies,
guidelines, and programs for effectively
reducing morbidity and mortality in
newborns and children having, or at risk
for, heritable disorders. In addition, the
Committee’s recommendations
regarding additional conditions/
heritable disorders for screening that
have been adopted by the Secretary are
included in the Recommended Uniform
Screening Panel (RUSP) and constitute
part of the comprehensive guidelines
supported by the Health Resources and
Services Administration. Pursuant to
section 2713 of the Public Health
Service Act, codified at 42 U.S.C.
300gg–13, non-grandfathered health
plans and group and individual health
insurance issuers are required to cover
evidence-informed care and screenings
included in the HRSA-supported
comprehensive guidelines without
charging a co-payment, co-insurance, or
deductible for plan years (in the
individual market, policy years)
beginning on or after the date that is 1
year from the Secretary’s adoption of the
condition for screening.
Agenda: The Committee will hear
presentations and discussions on topics
including an introduction on
sequencing and potential impact on
newborn screening and public health,
screening for Lysosomal Storage
Disorders, newborn screening
VerDate Sep<11>2014
17:01 Jul 26, 2016
Jkt 238001
timeliness, pilot studies for future
nominated conditions, and the National
Contingency Plan for Newborn
Screening. The Committee will hear
updates from the Laboratory Standards
and Procedures workgroup, Follow-up
and Treatment workgroup, and
Education and Training workgroup,
Timeliness workgroup, and the Cost
Analysis workgroup. Agenda items are
subject to changes as priorities indicate.
Tentatively, the Committee is expected
to review and/or vote on the
recommendations regarding the
information needed from pilot studies
for future nominated conditions. This
vote does not involve a proposed
addition of a condition to the RUSP.
The meeting agenda will be available 2
days prior to the meeting on the
Committee’s Web site: https://
www.hrsa.gov/advisorycommittees/
mchbadvisory/heritabledisorders.
Public Comments: Members of the
public may present oral comments and/
or submit written comments. Comments
are part of the official Committee record.
The public comment period is
tentatively scheduled for both days of
the meeting. Advance registration is
required to present oral comments and/
or submit written comments.
Registration information is at https://
www.blsmeetings.net/
ACHDNCAugust2016. The registration
deadline for public comments is Friday,
August 19, 2016, 11:59 p.m. Eastern
Time. Written comments must be
received by the deadline of Friday,
August 5, 2016, 11:59 p.m. Eastern Time
to be included in the August meeting
briefing book. Written comments should
identify the individual’s name, address,
email, telephone number, professional
or business affiliation, type of expertise
(i.e., parent, researcher, clinician, public
health, etc.), and the topic/subject
matter of comments. To ensure that all
individuals who have registered to make
oral comments can be accommodated,
the allocated time may be limited.
Individuals who are associated with
groups or have similar interests may be
requested to combine their comments
and present them through a single
representative. No audiovisual
presentations are permitted. For
additional information or questions on
public comments, please contact Alaina
Harris, Maternal and Child Health
Bureau, Health Resources and Services
Administration; email: aharris@
hrsa.gov.
Contact Person: Anyone interested in
obtaining other relevant information
should contact Alaina Harris, Maternal
and Child Health Bureau, Health
Resources and Services Administration,
Room 18W66, 5600 Fishers Lane,
PO 00000
Frm 00025
Fmt 4703
Sfmt 9990
Rockville, Maryland 20857; email:
aharris@hrsa.gov.
More information on the Advisory
Committee is available at https://
www.hrsa.gov/advisorycommittees/
mchbadvisory/heritabledisorders.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016–17724 Filed 7–26–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering,
Special Emphasis Panel, Center for Complex
Tissues (2017/01).
Date: October 24, 2016.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 959, Bethesda, MD 20892,
(240) 451–3398, hayesj@mail.nih.gov.
Dated: July 20, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–17655 Filed 7–26–16; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\27JYN1.SGM
27JYN1
]]>Agencies
[Federal Register Volume 81, Number 144 (Wednesday, July 27, 2016)]
[Notices]
[Page 49232]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-17655]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Biomedical Imaging and
Bioengineering, Special Emphasis Panel, Center for Complex Tissues
(2017/01).
Date: October 24, 2016.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, Suite
920, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D., Scientific Review Officer,
6707 Democracy Boulevard, Suite 959, Bethesda, MD 20892, (240) 451-
3398, hayesj@mail.nih.gov.
Dated: July 20, 2016.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-17655 Filed 7-26-16; 8:45 am]
BILLING CODE 4140-01-P
